Neuropilins are transmembrane glycoproteins that act as receptors for vascular endothelial growth factors (VEGF) and are involved in the process of tumor angiogenesis. Its importance in hematological malignancies such as acute leukemia (AL) remains to be elucidated. The aim of this study was to evaluate the significance of neuropilin-1 expression in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients by flowcytometry and the difference between both groups of acute leukemia. Bone marrow aspirates of 52 patients with acute leukemia, 29 patients with de novo AML and 23 ALL patients were examined in this study. 15 subjects with non-hematological malignancy serving as the control group were also included.
Introduction
Neuropilins are single-pass transmembrane glycoproteins that were found to be receptors for the vascular endothelial growth factor (VEGF) family.
CD304, or neuropilin-1 (NRP-1), is a transmembrane C-type lectin found on plasmacytoid dendritic cells (PDCs). VEGF is an important cytokine that contributes to disease evolution in various myeloid neoplasms. In particular, VEGF has been described as a mediator of malignant angiogenesis and autocrine growth regulator in leukemic cells [1] . It was found that NRP-1 binds to VEGF that is a critical pro-angiogenic factor that induces proliferation and migration of endothelial cells to tumor vasculature [2] .
Also, NRP-1enhances VEGF-mediated mitogenic and chemotactic activity [3] . VEGF, as a key factor for angiogenesis and tumor growth, exerts its functions mainly through activation of 2 tyrosine kinase receptors:
VEGFR-1 (Flt 1) and VEGFR-2 (KDR).
Experimental isoform, which does not bind NRP-1 and thus does not recruit BM cells, nor semaphorin 3A, which attracts cells but inhibits endothelial activation, is capable of sustaining arterial formation [4] .
Acute myeloid leukemia (AML) is the most common acute leukemia affecting adults, and its incidence increases with age [5] , while acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing nearly one-third of all pediatric cancers. With the advent of aggressive multimodality therapy, it has become a curable disease in more than 80% of patients [6] . BM angiogenesis is an important requirement for the development and progression of hematological malignancies including leukemia and lymphoma [7] . Leukemia is an angiogenesis-dependent malignancy and angiogenesis is strictly dependent on Akt/NF-κB(Protein kinase B (PKB)/ nuclear factor kappa-light-chain-enhancer of activated B cells)activation [8] .
The inhibitors of the NF-κB pathway decreasing VEGF secretion in leukemic cells and inhibiting endothelial cell activities may cause the interruption of a reciprocal stimulatory loop between leukemic and endothelial cells. Different reports demonstrating the activation of NF-κB in lymphoid and myeloid malignancies underscore the implication in malignant transformation [9] .
While the overexpression of NF-κB may lead to chemo resistance, the appropriate inhibition of this pathway may lead to successful therapy. Moreover, the transcription of VEGF by the classical NF-κB target gene may be repressed, which is one aspect of the participation in tumor genesis of adult T-cell leukemia (ATL) [10] . Thus, this work was planned to study of NRP-1 expression in acute leukemia patients by flow cytometry and if there is difference in its expression between AML and ALL.
Patients and Methods

Patients
This study was carried out on 52 newly diagnosed acute leukemia patients attending the 
Immunophenotypic Analysis:
Immunophenotypic analysis was performed using whole blood staining method. 
Detection of Surface Markers by Direct Staining:
The whole blood staining method was performed [13] . In short, 10 µL labeled MoAb was Significance was accepted at p 0.05.
Results
The present study was carried out on 52 newly diagnosed acute leukemia patients, 29 AML and 23 ALL patients. The demographic, clinical and hematological data of the studied AML, ALL patients and control group presented in (Tables 1, 2) . In AML patients, Neuropilin 
Control
Consent for Publication
Not applicable.
Availability of Data and Materials
All data generated or analyzed during this study are included in this published article.
Competing Interests
The authors declare that, they have no competing interests.
Funding
There is no funding for the research.
